Oncology

Welcome to the latest issue of EMJ Oncology! This e-journal brings you the latest news and novel findings from this year’s European Society…

In this supplement to EMJ Oncology, four leading researchers, Frederick Marmé, Christina Fotopoulou, Ursula Matulonis, and David Bowtell, discussed the impact of late diagnosis and delayed treatment on patient outcomes in ovarian cancer, genetic screening, and risk-reduction strategies. The evolving landscape of homologous recombination deficiency (HRD) testing and the importance of HRD testing at diagnosis are also explored.

During a symposium at the virtual European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2021, Eric Van Cutsem, Angela Lamarca, Nicola Normanno, and Arndt Vogel discussed better patient identification, biomarkers, genomic testing, and emerging therapies in the context of cholangiocarcinoma (CCA). The challenges associated with precision medicine were also explored.

In this supplement to EMJ Oncology, two internationally renowned experts, Andres J. Muñoz Martin and Annie Young, explored risk assessment…

OVARIAN cancer is the seventh most commonly diagnosed malignancy among women worldwide, and the gynaecologic cancer with the…

DURING a satellite symposium at the virtual 17th St Gallen International Breast Cancer Conference 2021, Dr Aleix Prat and Dr Giuseppe…

ONCOGENESIS in cholangiocarcinoma, a rare cancer, can be driven by the oncometabolite D-2-hydroxyglutarate, produced as a result…

FOUR leading experts in the field of oncology were brought together in an interview to discuss the epidemiology, treatment decisions…